Clinical Trial Update: Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating thymoglobulin induction with reduced doses of calcineurin inhibitors in liver transplant recipients to prevent rejection. The study sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Rejection
• Liver Transplantation

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• Tacrolimus (Tacrolimus)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Liver Dysfunction, Rejection, Transplant | Phase 2 | Status: COMPLETED